Effects of Peanut and Peanut Butter Consumption on Blood Lipids and Glycemic Control in Adults With Type 2 Diabetes

NCT00937222 | Completed DMC

• 1 other identifier: 59049
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Peanuts and peanut butter contain high levels of monounsaturated fat (MUFA), arginine, fiber, phytosterols, resveratrol and vitamin E that have the potential to reduce cardiovascular disease (CVD) risk through improved blood glucose control and favorable modification of blood lipids. When substituted for saturated fat in the diet, MUFA may have important metabolic benefits for persons with diabetes. Therefore, the investigators propose to study the effects of a peanut and peanut butter-enriched diet on markers of CVD risk factors in free-living adults with diabetes residing in Southern California. This study's primary clinical outcome will be high-density lipoprotein (HDL) - cholesterol. Secondary outcomes will include additional serum lipids (total cholesterol, low-density lipoprotein (LDL) - cholesterol and triacylglycerol), glucose, HbA1c, and anthropometry (body weight, body composition and waist circumference). This study will provide vital information about the role of peanuts and peanut butter in modulating blood glucose homeostasis and CVD risk factors among adults with diabetes.

Conditions

Type 2 Diabetes

Keywords

diabetes; cholesterol; peanuts; peanut butter; dietary intervention; HDL cholesterol

Outcome Measures

Primary Outcomes (1)

• The primary outcome measure is HDL-C

  12 weeks and 24 weeks

Secondary Outcomes (1)

• Serum lipids, glucose, HbA1c, anthropometrics and blood pressure

  12 weeks and 24 weeks

Interventions

Peanuts and peanut butter DIETARY_SUPPLEMENT

Peanuts and peanut butter

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Presence of a medical diagnosis of diabetes for at least 6 months
• HbA1c \< 9%
• Age greater than 18 years
• Resident of Loma Linda, California area

You may not qualify if:

• Allergy to peanuts
• Smokers
• History of irritable bowel disease or diverticulitis
• Statin therapy (unless stable statin dose for 3 months)

Sponsors & Collaborators

• Loma Linda University: lead
• National Peanut Board: collaborator

Study Sites (1)

Loma Linda University Medical Center Diabetes Treatment Center

Loma Linda, California, 92350, United States

Location

Related Publications (1)

• Wien M, Oda K, Sabate J. A randomized controlled trial to evaluate the effect of incorporating peanuts into an American Diabetes Association meal plan on the nutrient profile of the total diet and cardiometabolic parameters of adults with type 2 diabetes. Nutr J. 2014 Jan 22;13:10. doi: 10.1186/1475-2891-13-10.

  PMID: 24450471 DERIVED

Related Links

• Related Info

MeSH Terms

Conditions

Diabetes Mellitus, Type 2; Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Officials

• Joan Sabaté, MD, DrPh

  Chair, Department of Nutrition

  PRINCIPAL INVESTIGATOR

• Michelle Wien, DrPH

  Assistant Professor, Department of Nutrition

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: July 8, 2009
• First Posted: July 10, 2009
• Study Start: June 1, 2009
• Primary Completion: October 1, 2011
• Study Completion: October 1, 2011
• Last Updated: June 20, 2012

Record last verified: 2012-06

Locations

US (1)